Excellus BlueCross BlueShield partnering with Civica to increase access to affordable insulin

Posted on March 2, 2022

News Release

 

For Immediate Release                                                                                 Contact: Karen Feigel

Date: March 3, 2022                                                                                                       (585) 238-4308


Excellus BlueCross BlueShield partnering with Civica

to increase access to affordable insulin

Civica to manufacture and distribute three insulins for $30 or less per vial


ROCHESTER, NY - Today, Excellus BlueCross BlueShield, the Blue Cross Blue Shield Association (BCBSA) and other Blue Cross and Blue Shield (BCBS) companies joined Civica’s initiative to manufacture and distribute affordable insulins that, once approved, will be available to people living with diabetes at significantly lower prices than insulins currently on the market. The medications are expected to be available to all consumers for $30 or less per vial starting in 2024.

 

Excellus BCBS, BCBSA and BCBS companies are collaborating on this initiative with Civica and other partners across the health care industry, representing nearly every corner of the diabetes ecosystem.

 

“We’re proud to be part of this national collaboration to bring more affordable insulin and other medications to our communities,” said Mona Chitre, Pharm.D., chief pharmacy officer and vice president of Integrated Health Strategy for Excellus BCBS. “The Civica initiative will help us fulfill our critical role of controlling rising health care costs while also ensuring that more patients take their medication as prescribed since their prescription drugs will now be more affordable.”

 

“This is an important milestone in our continued partnership with Civica as we advance our shared goal of bringing lower-cost prescription medication directly to consumers,” said Kim Keck, president and CEO of BCBSA. “Access to affordable insulin can be the difference between life and death for diabetics – and we’re proud to be a part of Civica’s effort to ensure that millions of Americans have access to the medicine they need at a price they can afford. When we come together, we can make health care more affordable.”

More than eight million Americans rely on insulin to live, but as many as one in four insulin users report having to skip doses or take less than prescribed amounts due to the high cost of the medicine.[1] The financial burden has made the drug inaccessible for many and has led to patients developing health conditions that were once preventable.

 

Through this initiative, Civica will manufacture and distribute three analog insulins – glargine, lispro and aspart – which will be biosimilar drugs of the brand-name insulins Lantus, Humalog and Novolog. The insulins will be available in vials and prefilled pens at no more than $30 per vial or $55 for a box of five pens.

 

“Diabetes is arguably America’s most expensive chronic condition, and it is heartbreaking that millions

 

–more–

 

News release: Excellus BlueCross BlueShield Partnering with Civica – page 2

 

of people are rationing their care and putting their lives at risk because they can no longer afford insulin,” said Dan Liljenquist, board chair of Civica. “Through mission-driven partnerships, we are choosing to create a new market reality where no one is forced to ration essential diabetes medications.”

 

This insulin initiative is one of the many ways BCBS companies are partnering with Civica to increase access to safe and affordable medications. This announcement follows the founding of Civica’s subsidiary, CivicaScript, by BCBSA, 18 BCBS companies and Civica Rx to develop and manufacture common generic medications for which there is currently not enough market competition to drive down prices. The first of these lower-cost generic prescriptions are expected to be available to consumers through specialty and home delivery pharmacies later this year.

 

For more information on the insulin initiative, visit https://civicainsulin.org. For more information on CivicaScript, visit: https://www.bcbs.com/civica-rx.

 

 

###

 

About Excellus BlueCross BlueShield
Excellus BlueCross BlueShield, an independent licensee of the Blue Cross Blue Shield Association, is a nonprofit health plan with 1.5 million upstate New York members. The company's mission is to help people live healthier and more secure lives through access to high-quality, affordable health care. Its products and services include cost-saving prescription drug discounts, wellness tracking tools and access to telemedicine. With more than 3,500 employees, the company is committed to attracting and retaining a diverse workforce to foster innovation and better serve its members. It also encourages employees to engage in their communities by providing paid volunteer time off as one of many benefits. To learn more, visit
ExcellusBCBS.com.

About the Blue Cross Blue Shield Association
The Blue Cross and Blue Shield Association is a national federation of 34 independent, community-based and locally operated Blue Cross and Blue Shield companies that collectively provide health care coverage for one in three Americans.

[1] JAMA, Cost-Related Insulin Underuse Among Patients with Diabetes, 2019

Other Member News

Broadway in Syracuse
July 26, 2024

TICKETS FOR CAMERON MACKINTOSH’S ACCLAIMED PRODUCTION OF BOUBLIL AND SCHÖNBERG’S LES MISÉRABLES WILL GO ON SALE JULY 29TH AT 10AM

This reborn dream of a production looks and sounds fresher than ever. Sends shivers of excitement racing down the spine - You emerge feeling stirred and exhilarated.

Logo for Dannible & McKee, LLP
July 25, 2024

Dannible & McKee, LLP Announces the Promotion of 18 Professionals

The commitment to excellence from these 18 professionals is well demonstrated, and we congratulate them on their achievements.

Park Strategies Managing Director Featured in syracuse.com Article on New York's Cannabis Industry Rollout
July 24, 2024

Park Strategies Managing Director Featured in syracuse.com Article on New York's Cannabis Industry Rollout

His advocacy, born from an understanding of coalition-building and decision-making, has been influential amid many regulatory challenges.

Forbes Best Employers for Women logo
July 23, 2024

Excellus BlueCross BlueShield Recognized by Forbes as One of America’s Best Employers for Women 2024

This award highlights the organization’s ongoing commitment to fostering a diverse and inclusive workplace where women can thrive and advance their careers.

Ashley McGraw Architects
July 23, 2024

Ashley McGraw Architects Acquires studioMLA Architects, A National Leader in Early Education Design

Founded in 2006, studioMLA Architects is recognized as a national leader in the design of early education facilities along with nature-inspired playscapes for young children.

Mike Becallo
July 23, 2024

Michael Becallo Joins Oswego Health as Community Relations Representative

Originally from Cicero, Becallo is well-routed in CNY and brings over 15 years of healthcare experience.

Kate Weidman, Deputy Executive Director, AURORA of CNY
July 19, 2024

AURORA of CNY Announces Leadership Changes

Weidman will transition into the role of Executive Director following the retirement of current Executive Director Debra Chaiken, ensuring a seamless succession in leadership.

Credit Score 101
July 17, 2024

Credit Score 101 - Everything You Need to Know

Understanding and managing your credit score is a key step towards achieving financial stability and success. 

Larry Bousquet
July 16, 2024

Crouse Health Board of Directors Welcomes Two New Members

The Crouse Health Board of Directors has appointed two new directors.